ACE 抑制剂/血管紧张素受体阻滞剂降低癌症风险：一项基于人群的队列研究。
Lowered cancer risk with ACE inhibitors/ARBs: a population-based cohort study.
机构信息
Department of Anesthesiology, China Medical University Hospital, Taichung, Taiwan; Department of Health Services Administration, China Medical University, Taichung, Taiwan.
出版信息
J Clin Hypertens (Greenwich). 2014 Jan;16(1):27-33. doi: 10.1111/jch.12228. Epub 2013 Nov 8.
There are conflicting reports on cancer risk associated with angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor blockers (ARBs). This retrospective cohort study was conducted to analyze the risk of cancer development in patients who received ACE inhibitors/ARBs as treatment for essential hypertension. Using the Taiwan National Health Insurance Research Database, 297,688 eligible study patients with essential hypertension were identified. According to their antihypertensive prescriptions, the study patients were stratified into an ACE inhibitor group, an ARB group, or a control group. After matching, participants were observed for the occurrence of cancer. In the ACE inhibitor group compared with the control group, the hazard ratio was 0.51 (95% confidence interval, 0.39-0.68). In the ARB group compared with the control group, the hazard ratio was 0.8 (95% confidence interval, 0.65-0.97). Regular use of ACE inhibitors/ARBs was not associated with an increased risk of cancer development and was actually found to decrease overall cancer risk in this study.
关于血管紧张素转换酶（ACE）抑制剂/血管紧张素受体阻滞剂（ARB）相关的癌症风险存在相互矛盾的报告。本回顾性队列研究旨在分析接受 ACE 抑制剂/ARB 治疗原发性高血压患者癌症发展的风险。使用台湾全民健康保险研究数据库，确定了 297688 名符合条件的原发性高血压研究患者。根据他们的抗高血压处方，研究患者被分为 ACE 抑制剂组、ARB 组或对照组。匹配后，观察参与者癌症的发生情况。与对照组相比，ACE 抑制剂组的风险比为 0.51（95%置信区间，0.39-0.68）。与对照组相比，ARB 组的风险比为 0.8（95%置信区间，0.65-0.97）。本研究发现，常规使用 ACE 抑制剂/ARB 与癌症发展风险增加无关，实际上降低了整体癌症风险。
Zotero 插件